The sympathetic nervous system and the metabolic syndrome

被引:326
作者
Mancia, Giuseppe
Bousquet, Pascal
Elghozi, Jean Luc
Esler, Murray
Grassi, Guido
Julius, Stevo
Reid, John
Van Zwieten, Peter A.
机构
[1] Univ Milano Bicocca, Osped San Geraldo Tintori, I-20052 Monza, Milan, Italy
[2] Univ Strasbourg, Fac Med, Strasbourg, France
[3] Hop Necker Enfants Malad, UF Pharmacol Clin, Paris, France
[4] Baker Med Res Inst, Melbourne, Vic, Australia
[5] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA
[6] Univ Glasgow, Dept Med & Therapeut, Gardiner Inst, Glasgow, Lanark, Scotland
[7] Univ Amsterdam, Acad Med Ctr, Dept Pharmacotherapy, NL-1105 AZ Amsterdam, Netherlands
[8] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
[9] Univ Amsterdam, Acad Med Ctr, Dept Cardiopulm Surg, NL-1105 AZ Amsterdam, Netherlands
关键词
central sympatholytic drugs; hypertension; insulin; metabolic syndrome; obesity; sleep apnoea; sympathetic nervous system;
D O I
10.1097/HJH.0b013e328048d004
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Studies performed in the past two decades have unequivocally shown that several of the components of the metabolic syndrome are associated with indirect and direct markers of adrenergic overdrive. This is the case for hypertension and obesity, in which resting tachycardia, elevated plasma norepinephrine values, increased sympathetic nerve traffic, as well as augmented levels of total and regional norepinephrine spillover have been reported. This is also the case for insulin resistance, i.e. a metabolic condition frequently complicating the various components of the pathological condition identified as the 'metabolic syndrome'. After briefly describing the epidemiological and the cardiovascular risk profile of the disease, this paper will examine the behaviour of the sympathetic nervous system in the metabolic syndrome as well as the mechanisms potentially responsible for this neurogenic abnormality. This will be followed by an analysis of the role played by neuroadrenergic factors in disease progression as well as in the pathogenesis of its complications. Finally, the therapeutic implications of these findings will be highlighted.
引用
收藏
页码:909 / 920
页数:12
相关论文
共 131 条
[21]   Association between adiponectin and mediators of inflammation in obese women [J].
Engeli, S ;
Feldpausch, M ;
Gorzelniak, K ;
Hartwig, F ;
Heintze, U ;
Janke, J ;
Möhlig, M ;
Pfeiffer, AFH ;
Luft, FC ;
Sharma, AM .
DIABETES, 2003, 52 (04) :942-947
[22]   REGIONAL NOREPINEPHRINE TURNOVER IN HUMAN HYPERTENSION [J].
ESLER, M ;
LAMBERT, G ;
JENNINGS, G .
CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1989, 11 :75-89
[23]  
ESLER M, 1991, HYPERTENSION, V17, pS29
[24]   Mechanisms of sympathetic activation in obesity-related hypertension [J].
Esler, Murray ;
Straznicky, Nora ;
Eikelis, Nina ;
Masuo, Kazuko ;
Lambert, Gavin ;
Lambert, Elisabeth .
HYPERTENSION, 2006, 48 (05) :787-796
[25]   Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio study [J].
Ferrara, AL ;
Vaccaro, O ;
Cardoni, O ;
Panarelli, W ;
Laurenzi, M ;
Zanchetti, A .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2003, 13 (03) :126-132
[26]   INCREASED NOREPINEPHRINE SPILLOVER INTO THE JUGULAR VEINS IN ESSENTIAL-HYPERTENSION [J].
FERRIER, C ;
ESLER, MD ;
EISENHOFER, G ;
WALLIN, BG ;
HORNE, M ;
COX, HS ;
LAMBERT, G ;
JENNINGS, GL .
HYPERTENSION, 1992, 19 (01) :62-69
[27]   Insulin action, regional fat, and myocyte lipid: Altered relationships with increased adiposity [J].
Gan, SK ;
Kriketos, AD ;
Poynten, AM ;
Furler, SM ;
Thompson, CH ;
Kraegen, EW ;
Campbell, LV ;
Chisholm, DJ .
OBESITY RESEARCH, 2003, 11 (11) :1295-1305
[28]   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [J].
Gerstein, HC ;
Mann, JFE ;
Yi, QL ;
Zinman, B ;
Dinneen, SF ;
Hoogwerf, B ;
Hallé, JP ;
Young, J ;
Rashkow, A ;
Joyce, C ;
Nawaz, S ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (04) :421-426
[29]   Effects of heart rate changes on arterial distensibility in humans [J].
Giannattasio, C ;
Vincenti, A ;
Failla, M ;
Capra, A ;
Ciró, A ;
De Ceglia, S ;
Gentile, G ;
Brambilla, R ;
Mancia, G .
HYPERTENSION, 2003, 42 (03) :253-256
[30]   Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment [J].
Giannattasio, C ;
Mancia, G .
JOURNAL OF HYPERTENSION, 2002, 20 (10) :1889-1899